Thermo Fisher terminates $11.5B deal to acquire Qiagen

© Copyright ASC COMMUNICATIONS 2020. Intrigued in LINKING to or REPRINTING this content? View our policies by clicking here.

Qiagen stated it will get NeuMoDx, an incorporated molecular screening platform.

In accordance with the acquisition arrangement, the offer was ended, and Qiagen will pay Thermo Fisher $95 million in money repayment..

Maia Anderson –
Friday, August 14th, 2020
Print|Email.

More articles on supply chain: Northwell Health in talk with buy supply companyAtrium Health to eliminate single-use plasticsLabCorp, Quest Diagnostics say turnaround time for COVID-19 test results down to 1-3 days.

Thermo Fisher Scientific has actually ended its arrangement to acquire Qiagen for $11.5 billion, the business said Aug. 13..

Two-thirds of Qiagen shareholders were required to tender their shares by Aug. 10 for the deal to go through, and only 47 percent did..

The Waltham, Mass.-based life sciences business stated in March that it planned to acquire Qiagen, a Dutch diagnostics business. The offer was meant to expand Thermo Fishers capability to find infectious illness, such as COVID-19, and was anticipated to close in the first half of 2021..